The "female Viagra" drug Addyi officially hit the markets, but the reviews for the much anticipated drug at best remain mixed.

According to Mashable, among the biggest concerns outlined by critics is its history of past regulatory rejection, concerns about overall effectiveness and proper dosage and potentially troublesome effects when taken along with alcohol.

It all begs the question if the drug is worth the risk of having women subject themselves to all the potential side effects.

Over the last five years, the FDA twice rejected the legal sale of the drug flibanserin before an aggressive campaign by its manufacturers that included signing up women's groups to tout it as "a healthy, feminist-approved way for women to take control of their sex lives" dramatically aided in getting it over the top.

Critics argued the promotional push greatly overstated the drug's effectiveness and misrepresented data actually formed and collected in clinical trials.

"I don't know what else you could have had misinformation about," said New York University sex psychologist Leonore Tiefer.

Among those championing Addyi's cause was an impassioned female CEO and the male researcher who helped bring Viagra to the marketplace. The push to legalize the drug commenced in 1999, when German drug manufacturer Boehringer Ingelheim gathered hundreds of clinically depressed men and women to test a new antidepressant.

What the trials actually uncovered proved to be much more promising, at least in terms of potential profit margins. In time, researchers detected a noticeable boost in the number of women reporting heightened sex drives after taking the medication on a regular basis.

"They identified something that they weren't considering -- that this drug was pro-sexual as opposed to anti-sexual," says Irwin Goldstein, a foremost researcher in the sexual medicine field who has advocated on behalf of several sexual dysfunction drugs including Viagra.

By the time flibanserin actually gained FDA approval last August, Boehringer Ingelheim had been replaced by Sprout and the drug had gained a loyal following among its most ardent advocates.

Sprout CEO Cindy Whitehead insists her passionate embrace of the drug stems from her belief that women, like men, should also have their own place in the world of pharmaceuticals.

With that in mind and in the face of unrelenting criticism that the drug still caused such side effects as fainting, dizziness and nausea, Sprout based its promotional campaign on emotion as much as science.

Armed with a war chest of at least $100 million, it funded a coalition of women's groups that came to be known as "Even the Score," flying members of the group across the country to sing the virtues of the drug at various FDA panel advisory meetings.

Now it's time for the market to decide.